

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Tripartite motif-containing 24 (TRIM24)	<p><i>In vitro</i>, mouse and <i>Drosophila</i> studies suggest that inhibiting TRIM24 could help restore p53 tumor suppressor function to treat cancer. In transgenic mice, p53 bound Trim24. In <i>Drosophila</i>, mutation of the <i>Trim24</i> homolog <i>bonus</i> caused apoptosis that was preventable by deletion of <i>p53</i>, suggesting that Trim24 is a negative regulator of p53. Next steps include screening and testing inhibitors of TRIM24 enzymatic activity.</p> <p>SciBX 2(26); doi:10.1038/scibx.2009.1041 Published online July 9, 2009</p>	<p>International patent application filed for TRIM24 as a p53 modulator and cancer target; application exclusively licensed by CellCentric Ltd.; transgenic mice and stem cells available for licensing</p>	<p>Allton, K. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online June 22, 2009; doi:10.1073/pnas.0813177106 Contact: Michelle Craig Barton, University of Texas M.D. Anderson Cancer Center, Houston, Texas e-mail: mbarton@mdanderson.org</p>